PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) reported Monday a key development in its dual gene therapy program.
The Vancouver-based health sciences company said in a press release that it has identified at least four novel small interfering RNA (siRNA) constructs that target the gene of interest, while reducing its expression by at least 80% compared with a random siRNA control sequence. The gene therapy approach may have applications for diabetes and obesity.
The advance, according to PreveCeutical, sets the company on a path to creating a series of lead siRNA constructs, with the goal of employing innovative design strategies that enhance gene targeting specificity and biostability while maintaining exceptional gene silencing capacity.
“This is an important development in our dual gene therapy program,” Dr Harendra Parekh, the company’s chief research officer, said in a statement.
"The identified sequences are a fundamental piece in the gene therapy approach to potential applications for diabetes and obesity, representing the 'medicine' component of the proposed therapy.”
Shares of PreveCeutical fetched C$0.06 in Friday’s Canadian trading and US$0.04 on the OTC markets.
Last week, the company said it had completed a study of peptides to develop as non-addictive painkillers, with promising results.
Contact Dennis Fitzgerald at [email protected]